OVERLAND PARK, Kan., Dec. 15 Dechra Veterinary ProductsLLC today announces that the company has received FDA approval to marketVETORYL(R) Capsules.
VETORYL Capsules contain the drug trilostane, which has been demonstratedto be effective in the treatment of Cushing's syndrome in dogs. VETORYL willbe indicated for use in pituitary-dependent hyperadrenocorticism, whichcomprises the majority of cases of Cushing's syndrome in dogs. Additionally,VETORYL has received designation status as a Minor Use Drug for treatment ofhyperadrenocorticism caused by adrenal tumors -- the first drug to receive anapproval for this indication and the first drug to receive a Minor Usedesignation in dogs.
Mike Eldred, President of U.S. Operations, says, "We are very excited tohave approval to market this novel product in the U.S. Following its launch inJanuary, veterinarians will be able to source the product through our networkof distribution partners."
Dechra Veterinary Products LLC, located in Overland Park, Kansas, is theU.S. subsidiary of Dechra Pharmaceuticals PLC, a UK listed company focused oninternational animal healthcare markets. Dechra currently markets a range ofspecialized veterinary products in the U.S. For more information, please visithttp://www.dechra-us.com or call 866-933-2472.
SOURCE Dechra Veterinary Products LLC